Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept

<i>Background and Objectives</i>: Faricimab is the first intravitreal injection of vascular endothelial growth factor-A and angiopoietin-2 bispecific monoclonal antibody. Here, we evaluate the functional and anatomical outcomes of faricimab treatment in patients with diabetic macular ede...

Full description

Bibliographic Details
Main Authors: Hiromi Ohara, Yosuke Harada, Tomona Hiyama, Ayako Sadahide, Akira Minamoto, Yoshiaki Kiuchi
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Medicina
Subjects:
diabetic macular edema
faricimab
ranibizumab
aflibercept
vascular endothelial growth factor
angiopoietin-2
Online Access:https://www.mdpi.com/1648-9144/59/6/1125

Internet

https://www.mdpi.com/1648-9144/59/6/1125

Similar Items